切换至 "中华医学电子期刊资源库"

中华医学超声杂志(电子版) ›› 2023, Vol. 20 ›› Issue (09) : 930 -938. doi: 10.3877/cma.j.issn.1672-6448.2023.09.007

腹部超声影像学

超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究
丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔()   
  1. 300170 天津市第三中心医院超声科;300170 天津市重症疾病体外生命支持重点实验室,天津市人工细胞工程技术研究中心,天津市肝胆研究所
    300170 天津市第三中心医院放射科;300170 天津市重症疾病体外生命支持重点实验室,天津市人工细胞工程技术研究中心,天津市肝胆研究所
  • 收稿日期:2022-06-24 出版日期:2023-09-01
  • 通信作者: 经翔
  • 基金资助:
    国家自然科学基金(82371986); 天津市卫生健康科技项目(TJWJ2023XK022); 天津市医学重点学科(专科)建设项目(TJYXZDXK-074C)

Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study

Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing()   

  1. Department of Ultrasound, The Third Central Hospital, Tianjin 300170, China;Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China
    Department of Radiology, The Third Central Hospital, Tianjin 300170, China;Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Artificial Cell Engineering Technology Research Center, Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China
  • Received:2022-06-24 Published:2023-09-01
  • Corresponding author: Xiang Jing
引用本文:

丁建民, 秦正义, 张翔, 周燕, 周洪雨, 王彦冬, 经翔. 超声造影与普美显磁共振成像对具有高危因素的≤3 cm肝结节进行LI-RADS分类诊断的前瞻性研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 930-938.

Jianmin Ding, Zhengyi Qin, Xiang Zhang, Yan Zhou, Hongyu Zhou, Yandong Wang, Xiang Jing. Contrast-enhanced ultrasound versus gadoxetic acid-enhanced magnetic resonance imaging for LI-RADS classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma: a prospective study[J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2023, 20(09): 930-938.

目的

比较超声造影(CEUS)和普美显磁共振成像(EOB-MRI)两者肝脏影像报告和数据系统(LI-RADS)对具有肝细胞癌(HCC)高危因素的≤3 cm的肝局灶性病变分类的一致性和诊断效能。

方法

前瞻性收集天津市第三中心医院同时接受CEUS和EOB-MRI检查且具有HCC高危因素的结节直径≤3 cm的病例。在对患者信息、病理及相关检查均未知的情况下,对每个肝结节的CEUS及EOB-MRI图像进行观察,利用Kappa值评估观察者间一致性,分别按照CEUS LI-RADS(2017年版)及CT/MRI LI-RADS(2018年版)标准对结节进行分类。恶性病灶诊断以病理结果、良性病灶以病理结果和(或)随访作为参考标准,计算2种影像方式LI-RADS分类的诊断效能,利用χ2检验及Z检验比较两者诊断效能的差异。

结果

107例114个结节满足入排标准。CEUS、EOB-MRI分类中LR-5、LR-4、LR-3和LR-M类结节的数量分别占45.6%、11.4%、19.3%、23.7%和25.4%、57.9%、10.5%、6.1%,2种影像方式对结节分类的一致性较差(Kappa=0.17,P<0.001)。CEUS LI-RADS和EOB-MRI LI-RADS分类各自观察者之间一致性良好(Kappa=0.83、0.77,P<0.001)。CEUS和EOB-MRI LR-5、LR-4、LR-3类对HCC的阳性预测值分别为98.1%、38.5%、13.6%和100%、71.2%、16.7%。CEUS和EOB-MRI LR-5类诊断HCC的敏感度、特异度、曲线下面积(AUC)分别为64.6%、97.1%、0.81和36.7%、100%、0.68。两者的阳性预测值、特异度差异均无统计学意义,AUC差异具有统计学意义(Z=4.29,P<0.01)。

结论

CEUS和EOB-MRI对≤3 cm肝结节的分类一致性较差;两者各自LI-RADS分类不同观察者之间一致性较好。CEUS与EOB-MRI LR-5类对≤3 cm HCC具有同等良好的阳性预测值和特异度。

Objective

To compare the consistency and diagnostic performance of contrast-enhanced ultrasound (CEUS) versus gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) in liver imaging reporting and data system (LI-RADS) classification of focal liver lesions ≤3 cm in patients at high risk of hepatocellular carcinoma (HCC).

Methods

Patients with focal liver lesions ≤3 cm at high risk of HCC who underwent CEUS and EOB-MRI at Tianjin Third Central Hospital were prospectively collected. The CEUS and EOB-MRI images of each liver nodule were observed to evaluate interobserver consistency using kappa coefficient and category according to the CEUS LI-RADS V2017 and CT/MRI LI-RADS V2018 criteria in a double blind manner. Pathology was used as the reference standard of malignant lesions and pathology and/or follow-up results were used as the reference standard for benign lesions to calculate the diagnostic performance of the two modalities, and χ2 test and Z test were used to compare the difference between the two modalities.

Results

A total of 114 nodules of 107 cases met the inclusion criteria. The proportions of LR-5, LR-4, LR-3, and LR-M diagnosed by CEUS and EOB-MRI accounted for 45.6%, 11.4%, 19.3%, and 23.7%, and 25.4%, 57.9%, 10.5%, and 6.1%, respectively. The consistency of nodule classification between the two modalities was poor (Kappa=0.17, P<0.001). There was good consistency between readers on CEUS LI-RADS and EOB-MRI LI-RADS (Kappa=0.83 and 0.77, P<0.001). The positive predictive values of CEUS and EOB-MRI LR-5, LR-4, and LR-3 for HCC were 98.1%, 38.5%, and 13.6%, and 100%, 71.2%, and 16.7%, respectively. The sensitivity, specificity, and area under the curve (AUC) of CEUS and EOB-MRI LR-5 for HCC were 64.6%, 97.1%, and 0.81, and 36.7%, 100%, and 0.68, respectively. The was no statistical difference in the positive predictive value or specificity between the two groups, while the difference of AUC was statistically significant (Z=4.29, P<0.01).

Conclusion

CEUS and EOB-MRI have poor consistency in classification of liver nodules ≤ 3 cm. The consistency between readers is good. CEUS and EOB-MRI LR-5 have equally good diagnostic performance for HCC ≤ 3 cm.

表1 超声造影肝脏影像报告和数据系统分类观察者之间一致性评价(个)
表2 普美显磁共振成像肝脏影像报告和数据系统分类观察者之间一致性评价(个)
表3 超声造影和普美显磁共振成像肝脏影像报告和数据系统分类结果对照(个)
图1 患者男性,43岁,肝S5-8区病灶,大小1.7 cm×1.6 cm,既往乙肝肝硬化病史。EOB-MRI分类LR-5类:图a示T1加权成像扫查发现S5-8区结节呈低信号;图b:结节在动脉期明显强化呈高信号;图c示门脉期出现廓清,呈低信号;图d示移行期呈低信号;图e示肝胆期呈低信号;图f示常规超声扫查发现S5-8区低回声结节;CEUS分类LR-5类:图g示动脉期表现为高增强;图h示门脉期60 s未见廓清;图i示延迟期呈低增强。超声引导下穿刺组织学活检病理结果为高分化肝细胞癌
图2 患者男性,51岁,肝S6区病灶,大小2.0 cm×1.6 cm,既往乙肝肝硬化病史。EOB-MRI分类LR-4类:图a示T1加权成像扫查发现S6区结节呈稍低信号,欠均匀;图b示结节在动脉期轻度强化呈高信号,欠均匀;图c示门脉期呈高信号;图d示移行期呈等信号,欠均匀;图e示肝胆期呈低信号;图f示常规超声扫查发现S6区低回声结节;CEUS分类LR-M类:图g示动脉期表现为高增强;图h示门静脉期58 s开始廓清;图i示延迟期呈低增强。超声引导下穿刺组织学活检病理结果为高分化肝细胞癌
表4 超声造影与普美显磁共振成像肝脏影像报告和数据系统分类结果与病理对照(个)
图3 超声造影(CEUS)和普美显磁共振成像(EOB-MRI)肝脏影像报告和数据系统LR-5类诊断肝细胞癌的受试者操作特征曲线
图4 超声造影和普美显磁共振成像(EOB-MRI)肝脏影像报告和数据系统LR-M类诊断非肝细胞癌恶性肿瘤的受试者操作特征曲线比较
表5 CEUS与EOB-MRI的LR-5、LR-M类诊断效能比较
1
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin, 2021, 71(3): 209-249.
2
Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update [J]. Hepatology, 2011, 53(3): 1020-1022.
3
Guang Y, Xie L, Ding H, et al. Diagnosis value of focal liver lesions with SonoVue(R)-enhanced ultrasound compared with contrast-enhanced computed tomography and contrast-enhanced MRI: a meta-analysis [J]. J Cancer Res Clin Oncol, 2011, 137(11): 1595-1605.
4
Zhang XY, Luo Y, Wen TF, et al. Contrast-enhanced ultrasound: Improving the preoperative staging of hepatocellular carcinoma and guiding individual treatment [J]. World J Gastroenterol, 2014, 20(35): 12628-12636.
5
Lee YJ, Lee JM, Lee JS, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR imaging—a systematic review and meta-analysis [J]. Radiology, 2015, 275(1): 97-109.
6
Di Martino M, Marin D, Guerrisi A, et al. Intraindividual comparison of gadoxetate disodium–enhanced MR imaging and 64-section multidetector CT in the detection of hepatocellular carcinoma in patients with cirrhosis [J]. Radiology, 2010, 256(3): 806-816.
7
Guo J, Seo Y, Ren S, et al. Diagnostic performance of contrast-enhanced multidetector computed tomography and gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a metaanalysis [J]. Abdom Radiol (NY), 2016, 41(10): 1960-1972.
8
American College of Radiology. CEUS Liver Imaging Reporting and Data System Version 2018 [EB/OL]. Accessed May 25 2022.
9
American College of Radiology. CT/MRI Liver Imaging Reporting and Data System Version 2018 [EB/OL]. Accessed May 25 2022.
10
Ding J, Long L, Zhang X, et al. Contrast-enhanced ultrasound LI-RADS 2017: comparison with CT/MRI LI-RADS [J]. Eur Radiol, 2021, 31(2): 847-854.
11
Schellhaas B, Hammon M, Strobel D, et al. Interobserver and intermodality agreement of standardized algorithms for non-invasive diagnosis of hepatocellular carcinoma in high-risk patients: CEUS-LI-RADS versus MRI-LI-RADS [J]. Eur Radiol, 2018, 28(10): 4254-4264.
12
Wilson SR, Lyshchik A, Piscaglia F, et al. CEUS LI-RADS: algorithm, implementation, and key differences from CT/MRI [J]. Abdom Radiol (NY), 2018, 43(1): 127-142.
13
Kim TK, Noh SY, Wilson SR, et al. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017-a review of important differences compared to the CT/MRI system [J]. Clin Mol Hepatol, 2017, 23(4): 280-289.
14
Kim BR, Lee JM, Lee DH, et al. Diagnostic performance of gadoxetic acid-enhanced liver MR imaging versus multidetector CT in the detection of dysplastic nodules and early hepatocellular carcinoma [J]. Radiology, 2017, 285(1): 134-146.
15
Kang JH, Choi SH, Lee JS, et al. Interreader agreement of liver imaging reporting and data system on MRI: a systematic review and meta-analysis [J]. J Magn Reson Imaging, 2020, 52(3): 795-804.
16
Huang JY, Li JW, Lu Q, et al. Diagnostic accuracy of CEUS LI-RADS for the characterization of liver nodules 20 mm or smaller in patients at risk for hepatocellular carcinoma [J]. Radiology, 2020, 294(2): 329-339.
17
Clarke CGD, Albazaz R, Smith CR, et al. Comparison of LI-RADS with other non-invasive liver MRI criteria and radiological opinion for diagnosing hepatocellular carcinoma in cirrhotic livers using gadoxetic acid with histopathological explant correlation [J]. Clin Radiol, 2021, 76(5): 333-341.
18
Kim YY, An C, Kim S, et al. Diagnostic accuracy of prospective application of the Liver Imaging Reporting and Data System (LI-RADS) in gadoxetate-enhanced MRI [J]. Eur Radiol, 2018, 28(5): 2038-2046.
19
Min JH, Kim JM, Kim YK, et al. EASL versus LI-RADS: Intra-individual comparison of MRI with extracellular contrast and gadoxetic acid for diagnosis of small HCC [J]. Liver Int, 2021, 41(12): 2986-2996.
20
Min JH, Kim JM, Kim YK, et al. Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the liver imaging reporting and data system [J]. Hepatology, 2018, 68(6): 2254-2266.
21
Kim YY, Kim MJ, Kim EH, et al. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: performance of LI-RADS version 2018 [J]. Radiology, 2019, 291(1): 72-80.
22
Joo I, Lee JM, Lee DH, et al. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? [J]. Eur Radiol, 2019, 29(4): 1724-1732.
[1] 吕琦, 惠品晶, 丁亚芳, 颜燕红. 颈动脉斑块易损性的超声造影评估及与缺血性卒中的相关性研究[J]. 中华医学超声杂志(电子版), 2023, 20(10): 1040-1045.
[2] 丁雷, 罗文, 杨晓, 庞丽娜, 张佩蒂, 刘海静, 袁佳妮, 刘瑾. 高帧频超声造影在评价C-TIRADS 4-5类甲状腺结节成像特征中的应用[J]. 中华医学超声杂志(电子版), 2023, 20(09): 887-894.
[3] 张茜, 陈佳慧, 高雪萌, 赵傲雪, 黄瑛. 基于高帧频超声造影的影像组学特征鉴别诊断甲状腺结节良恶性的价值[J]. 中华医学超声杂志(电子版), 2023, 20(09): 895-903.
[4] 朱连华, 费翔, 韩鹏, 姜波, 李楠, 罗渝昆. 高帧频超声造影在胆囊息肉样病变中的鉴别诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(09): 904-910.
[5] 李淼, 朱连华, 韩鹏, 姜波, 费翔. 高帧频超声造影评价肝细胞癌血管形态与风险因素的研究[J]. 中华医学超声杂志(电子版), 2023, 20(09): 911-915.
[6] 张卫平, 王婧玲, 刘志兴, 陈莉, 谌芳群. 肾透明细胞癌高帧频超声造影时间-强度曲线特征分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 916-922.
[7] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 939-944.
[8] 刘嘉嘉, 王承华, 陈绪娇, 刘瑗玲, 王善钰, 屈海花, 张莉. 经阴道子宫-输卵管实时三维超声造影中患者疼痛发生情况及其影响因素分析[J]. 中华医学超声杂志(电子版), 2023, 20(09): 959-965.
[9] 邵华, 那子悦, 荆慧, 李博, 王秋程, 程文. 术前经皮超声造影对乳腺癌腋窝前哨淋巴结转移及负荷的诊断价值[J]. 中华医学超声杂志(电子版), 2023, 20(08): 849-853.
[10] 张旭, 徐建平, 苏冬明, 王彩芬, 王大力, 张文智. 男性乳腺肿块的超声造影特征[J]. 中华医学超声杂志(电子版), 2023, 20(08): 854-859.
[11] 谢迎东, 孙帼, 徐超丽, 杨斌, 孙晖, 戴云. 超声造影定量评价不同生存期移植肾血流灌注的临床价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 749-754.
[12] 王晗宇, 张司可, 张羽, 万欣, 贺秋霞, 李明明, 杨秀华. 超声造影在脑胶质瘤切除术术中的应用价值[J]. 中华医学超声杂志(电子版), 2023, 20(07): 755-760.
[13] 蒋佳纯, 王晓冰, 陈培荣, 许世豪. 血清学指标联合常规超声及超声造影评分诊断原发性干燥综合征的临床价值[J]. 中华医学超声杂志(电子版), 2023, 20(06): 622-630.
[14] 董杰, 杨松, 杨浩, 陈翔, 张万里. 乙酰辅酶A羧化酶2基因高甲基化与肝细胞癌临床病理因素和生存期的关系[J]. 中华普通外科学文献(电子版), 2023, 17(06): 433-437.
[15] 廖梅, 张红君, 金洁玚, 吕艳, 任杰. 床旁超声造影对肝移植术后早期肝动脉血栓的诊断价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 630-634.
阅读次数
全文


摘要